Skip to main content
SpringerLink
Log in

Tailored Surgery for Early Breast Cancer: Biological Aspects

  • Chapter
Book cover Breast Cancer and Molecular Medicine

  • 999 Accesses

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 249.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rutgers EJ; EUSOMA Consensus Group. Quality control in the locoregional treatment of breast cancer. Eur J Cancer 2001;37(4):447–53

    Article  PubMed  CAS  Google Scholar 

  2. Morrow M, White J, Moughan J, et al. Factors predicting the use of breast-conserving therapy in stage I and II breast carcinoma. J Clin Oncol 2001;19(8):2254–62

    PubMed  CAS  Google Scholar 

  3. Vrieling C, Collette L, Fourquet A, et al. The influence of patient, tumor and treatment factors on the cosmetic results after breast-conserving therapy in the EORTC ‘boost vs. no boost’ trial. EORTC Radiotherapy and Breast Cancer Cooperative Groups. Radiother Oncol 2000;55(3):219–32

    Article  PubMed  CAS  Google Scholar 

  4. Van Dongen JA, Voogd AC, Fentiman IS, et al. Long-term results of a randomized trial comparing breast-conserving therapy with mastectomy: European Organization for Research and Treatment of Cancer 10801 trial. J Natl Cancer Inst 2000;92(14):1143–50

    Article  PubMed  Google Scholar 

  5. Veronesi U, Cascinelli N, Mariani L, et al. Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002;347(16):1227–32

    Article  PubMed  Google Scholar 

  6. Fisher B, Anderson S, Bryant J, et al. Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer. N Engl J Med 2002;347(16):1233–41

    Article  PubMed  Google Scholar 

  7. Van der Hage JA, Putter H, Bonnema J, Bartelink H, Therasse P, van de Velde CJ; EORTC Breast Cancer Group. Impact of locoregional treatment on the early-stage breast cancer patients: a retrospective analysis. Eur J Cancer 2003;39(15):2192–9

    Article  PubMed  Google Scholar 

  8. Van Tienhoven G, Voogd AC, Peterse JL, et al. Prognosis after treatment for loco regional recurrence after mastectomy or breast conserving therapy in two randomised trials (EORTC 10801 and DBCG-82TM). EORTC Breast Cancer Cooperative Group and the Danish Breast Cancer Cooperative Group. Eur J Cancer 1999;35:32–8

    Article  PubMed  Google Scholar 

  9. Carter CL, Allen C, Henson DE. Relation to tumor size, lymph node status and survival in 24,740 breast cancer cases. Cancer 1989;63(1):181–7

    Article  PubMed  CAS  Google Scholar 

  10. Veronesi U, Paganelli G, Viale G, et al. A randomized comparison of sentinel-node biopsy with routine axillary dissection in breast cancer. N Engl J Med 2003;349(6):546–53

    Article  PubMed  Google Scholar 

  11. Rutgers EJ. Sentinel node procedure in breast carcinoma: a valid tool to omit unnecessary axillary treatment or even more? Eur J Cancer 2004;40(2):182–6

    Article  PubMed  CAS  Google Scholar 

  12. Holland R, Veling SHJ, Mravunac M, Hendriks JHCL. Histologic multifocality of Tis, T1-2 carcinomas: implications for clinical trials of breast-conserving surgery. Cancer 1985;56:979–90

    Article  PubMed  CAS  Google Scholar 

  13. Schnitt SJ, Abner A, Gelman R, et al. The relationship between microscopic margins of resection and the risk of local recurrence in patients with breast cancer treated with breast-conserving surgery and radiation therapy. Cancer 1994;74:1746–51.

    Article  PubMed  CAS  Google Scholar 

  14. Fourquet A, Campana F, Zafrani B, Mosseri V, Vielh P, Durand J-C, Vilcoq JR. Prognostic factors of breast recurrence in the conservative management of early breast cancer: a 25-year follow-up. Int J Radiat Oncol Biol Phys 1989;17:719–25

    PubMed  CAS  Google Scholar 

  15. Borger J, Kemperman H, Hart A, Peterse H, Dongen van J, Bartelink H. Risk factors in breast-conservation therapy. J Clin Oncol 1994;12:653–60

    PubMed  CAS  Google Scholar 

  16. Goldstein NS, Kestin L, Vicini F. Factors associated with ipsilateral breast failure and distant metastases in patients with invasive breast carcinoma treated with breast-conserving therapy. A clinicopathologic study of 607 neoplasms from 583 patients. Am J Clin Pathol 2003;120(4):500–27

    Article  PubMed  Google Scholar 

  17. Asgeirsson KS, McCulley SJ, Pinder SE, Macmillan RD. Size of invasive breast cancer and risk of local recurrence after breast-conservation therapy. Eur J Cancer 2003;39(17):2462–9

    Article  PubMed  CAS  Google Scholar 

  18. Clarke DH, Le MG, Sarrazin D, Lacombe M-J, Fontaine F, Travagli J-P, May-Levin F, Contesso G, Arriagada R. Analysis of local-regional relapses in patients with early breast cancers treated by excision and radiotherapy: experience of the Institut Gustave-Roussy. Int J Radiat Oncol Biol Phys 1985;11:137–45

    PubMed  CAS  Google Scholar 

  19. Fisher ER, Anderson S, Redmond C, Fisher B. Ipsilateral breast tumor recurrence and survival following lumpectomy and irradiation: pathological findings from NSABP protocol B-06. Semin Surg Oncol 1992;8:161–6

    PubMed  CAS  Google Scholar 

  20. Kurtz JM, Jacquemier J, Torhorst J, Spitalier J-M, Amalric R, Hunig R, Walther E, Harder F, Almendral A, Brandone H, Ayme Y, Roth J. Conservation therapy for breast cancers other than infiltrating ductal carcinoma. Cancer 1989;63:1630–5

    Article  PubMed  CAS  Google Scholar 

  21. Elkhuizen PHM, van de Vijver MJ, Hermans J, Zonderland HM, van de Velde CJH, Leer JWH. Local recurrence after breast conserving treatment: high incidence in young patients and association with poor survival. Int J Rad Oncol Biol Phys 1998;40:859–67

    Article  CAS  Google Scholar 

  22. Recht A, Gray R, Davidson NE, Fowble BL, Solin LJ, Cummings FJ, Falkson G, Falkson HC, Taylor SG, Tormey DC. Locoregional failure 10 years after mastectomy and adjuvant chemotherapy with or without tamoxifen without irradiation: experience of the Eastern Cooperative Oncology Group. J Clin Oncol 1999;17:1689–1700

    PubMed  CAS  Google Scholar 

  23. Fowble BL, Gray R, Gilchrist K, Goodman RL, Taylor S, Tormey DC. Identification of a subgroup of patients with breast cancer and histologically positive axillary nodes receiving adjuvant chemotherapy who may benefit from postoperative radiotherapy. J Clin Oncol 1988;6:1107–17

    PubMed  CAS  Google Scholar 

  24. Voogd AC, Nielsen M, Peterse JL, et al. Danish Breast Cancer Cooperative Group. Breast Cancer Cooperative Group of the European Organization for Research and Treatment of Cancer. Differences in risk factors for local and distant recurrence after breast-conserving therapy or mastectomy for stage I and II breast cancer: pooled results of two large European randomized trials. J Clin Oncol 2001;19(6):1688–97

    PubMed  CAS  Google Scholar 

  25. Vrieling C, Collette L, Fourquet A, et al. EORTC Radiotherapy, Breast Cancer Groups. Can patient-, treatment-and pathology-related characteristics explain the high local recurrence rate following breast-conserving therapy in young patients? Eur J Cancer 2003;39(7):932–44

    Article  PubMed  CAS  Google Scholar 

  26. Arriagada R, Le MG, Contesso G, Guinebretiere JM, Rochard F, Spielmann M. Predictive factors for local recurrence in 2006 patients with surgically resected small breast cancer. Ann Oncol 2002;13(9):1404–13

    Article  PubMed  CAS  Google Scholar 

  27. Pierce LJ, Strawderman M, Narod SA, et al. Effect of radiotherapy after breast-conserving treatment in women with breast cancer and germline BRCA1/2 mutations. J Clin Oncol 2000;18(19):3360–9

    PubMed  CAS  Google Scholar 

  28. Turner BC, Harrold E, Matloff E, et al. BRCA1/BRCA2 germline mutations in locally recurrent breast cancer patients after lumpectomy and radiation therapy: implications for breast-conserving management in patients with BRCA1/BRCA2 mutations. J Clin Oncol 1999;17(10):3017–24

    PubMed  CAS  Google Scholar 

  29. Haffty BG, Harrold E, Khan AJ, et al. Outcome of conservatively managed early-onset breast cancer by BRCA1/2 status. Lancet 2002;359(9316):1471–7

    Article  PubMed  Google Scholar 

  30. Van de Vijver MJ, Peterse JL, Mooi WJ, Wisman P, Lomans J, Dalesio O, Nusse R. Neu-protein overexpression in breast cancer. Association with comedo-type ductal carcinoma and limited prognostic value in stage II breast cancer. N Engl J Med 1988;319:1239–45

    Article  PubMed  Google Scholar 

  31. Ramachandra S, Machin L, Ashley S, Monaghan P, Gusterson BA. Immunohistochemical distribution of c-erbB-2 in situ breast carcinoma-a detailed morphological analysis. J Pathol 1990;61:7–14

    Article  Google Scholar 

  32. Lowe SW, Bodis S, McClatchey A, Remington L, Ruley HE, Fisher DE, Housman DE, Jacks T. p53 status and the efficacy of cancer therapy in vivo. Science 1994;266:807–10

    Article  PubMed  CAS  Google Scholar 

  33. O’Connor PM, Jackman J, Jondle D, et al. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitt’s lymphoma cell lines. Cancer Res 1993;53:4776–80

    PubMed  CAS  Google Scholar 

  34. Koukourakis MI, Giatromanolaki A, Galazios G, Sivridis E. Molecular analysis of local relapse in high-risk breast cancer patients: can radiotherapy fractionation and time factors make a difference? Br J Cancer 2003;88(5):711–17

    Article  PubMed  CAS  Google Scholar 

  35. Haffty BG. Molecular and genetic markers in the local-regional management of breast cancer. Semin Radiat Oncol 2002;12(4):329–40

    Article  PubMed  Google Scholar 

  36. Halsted WS. The results of radical operations for the cure of carcinoma of the breast. Ann Surg 1907;66:1

    Article  Google Scholar 

  37. Fisher B, Slack NH. Number of lymph nodes examined and the prognosis of breast carcinoma. Surg Gynecol Obstet 1970;131(1):79–88

    PubMed  CAS  Google Scholar 

  38. Bonadonna G, Brusamolino E, Valagussa P, et al. Combination chemotherapy as an adjuvant treatment in operable breast cancer. N Engl J Med 1976;294(8):405–10

    Article  PubMed  CAS  Google Scholar 

  39. Fisher B, Carbone P, Economou SG, et al. 1-Phenylalanine mustard (L-PAM) in the management of primary breast cancer. A report of early findings. N Engl J Med 1975;292(3):117–22

    Article  PubMed  CAS  Google Scholar 

  40. Polychemotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;352(9132):930–42

    Article  Google Scholar 

  41. Tamoxifen for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists’ Collaborative Group. Lancet 1998;351(9114):1451–67

    Article  Google Scholar 

  42. Goldhirsch A, Wood WC, Gelber RD, Coates AS, Thurlimann B, Senn HJ. Meeting highlights: updated international expert consensus on the primary therapy of early breast cancer. J Clin Oncol 2003;21(17):3357–65

    Article  PubMed  Google Scholar 

  43. Fisher B, Jeong JH, Anderson S, et al. Twenty-five-year follow-up of a randomized trial comparing radical mastectomy, total mastectomy, and total mastectomy followed by irradiation. N Engl J Med 2002;347(8):567–75

    Article  PubMed  Google Scholar 

  44. Orr RK. The impact of prophylactic axillary node dissection on breast cancer survival — a Bayesian meta-analysis. Ann Surg Oncol 1999;6(1):109–16

    Article  PubMed  CAS  Google Scholar 

  45. Van de Vijver MJ, He YD, van’t Veer LJ, et al. A gene-expression signature as a predictor of survival in breast cancer. N Engl J Med 2002;347(25):1999–2009

    Article  PubMed  Google Scholar 

  46. Rutgers EJ, Nieweg OE. Finding lymph node metastases in invasive breast cancer: sampling or sentinel node procedure? Eur J Surg Oncol 2002;28(6):569–70

    Article  PubMed  CAS  Google Scholar 

  47. Silverstein MJ, Skinner KA, Lomis TJ. Predicting axillary nodal positivity in 2282 patients with breast carcinoma. World J Surg 2001;25(6):767–72

    Article  PubMed  CAS  Google Scholar 

  48. Schneidereit NP, Davis N, Mackinnon M, Speers CH, Truong PT, Olivotto IA. T1a breast carcinoma and the role of axillary dissection. Arch Surg 2003;138(8):832–7

    Article  PubMed  Google Scholar 

  49. Lara JF, Young SM, Velilla RE, Santoro EJ, Templeton SF. The relevance of occult axillary micrometastasis in ductal carcinoma in situ: a clinicopathologic study with long-term follow-up. Cancer 2003;98(10):2105–13

    Article  PubMed  Google Scholar 

  50. Lindahl T, Engel G, Ahlgren J, et al Can axillary dissection be avoided by improved molecular biological diagnosis? Acta Oncol 2000;39(3):319–26. Review

    Article  PubMed  CAS  Google Scholar 

  51. Mannweiler S, Tsybrovskyy O, Regauer S. The flow cytometric DNA index can predict the presence of lymph node metastases in invasive ductal breast carcinoma. APMIS 2002;110(7–8):580–6

    Article  PubMed  Google Scholar 

  52. Friedman NS, Freedman MD. Correlation of DNA flow cytometry and hormone receptors with axillary lymph node status in patients with carcinoma of the breast. Md Med J 1994 Nov;43(11):963–5

    PubMed  CAS  Google Scholar 

  53. Schmidt H, Wei JP, Yeh KA. Predictive value of flow cytometry for metastatic potential in breast cancer. Am Surg 1999;65(5):434–8

    PubMed  CAS  Google Scholar 

  54. West M, Blanchette C, Dressman H, et al. Predicting the clinical status of human breast cancer by using gene expression profiles. Proc Natl Acad Sci U S A 2001;98(20):11462–7

    Article  PubMed  CAS  Google Scholar 

  55. Veronesi U, Rilke F, Luini A, Sacchini V, Galimberti V, Campa T, Dei Bei E, Greco M, Magni A, Merson M, et al. Distribution of axillary node metastases by level of invasion. An analysis of 539 cases. Cancer 1987;59(4):682–7

    Article  PubMed  CAS  Google Scholar 

  56. Giuliano AE, Kirgan DM, Guenther JM, Morton DL. Lymphatic mapping and sentinel lymphadenectomy for breast cancer. Ann Surg 1994;220(3):391–8

    Article  PubMed  CAS  Google Scholar 

  57. Nieweg OE, Jansen L, Valdes Olmos RA, Rutgers EJ, Peterse JL, Hoefnagel KA, Kroon BB. Lymphatic mapping and sentinel lymph node biopsy in breast cancer. Eur J Nucl Med 1999;26(4 Suppl):S11–6

    Article  PubMed  CAS  Google Scholar 

  58. Veronesi U, Cascinelli N, Greco M, Bufalino R, Morabito A, Galluzzo D, Conti R, De Lellis R, Delle Donne V, Piotti P, et al. Prognosis of breast cancer patients after mastectomy and dissection of internal mammary nodes. Ann Surg 1985;202(6):702–7

    Article  PubMed  CAS  Google Scholar 

  59. Tanis PJ, Nieweg OE, Valdes Olmos RA, Peterse JL, Rutgers EJ, Hoefnagel CA, Kroon BB. Impact of non-axillary sentinel node biopsy on staging and treatment of breast cancer patients. Br J Cancer 2002;87(7):705–10

    Article  PubMed  CAS  Google Scholar 

  60. Fisher ER, Costantino J, Fisher B, Redmond C. Pathologic findings from the National Surgical Adjuvant Breast Project (Protocol 4). Discriminants for 15-year survival. National Surgical Adjuvant Breast and Bowel Project Investigators. Cancer 1993;71(6 Suppl):2141–50

    Article  PubMed  CAS  Google Scholar 

  61. Overgaard M, Hansen PS, Overgaard J, Rose C, Andersson M, Bach F, Kjaer M, Gadeberg CC, Mouridsen HT, Jensen MB, Zedeler K. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med 1997;337(14):949–55

    Article  PubMed  CAS  Google Scholar 

  62. Axelsson CK, Mouridsen HT, Zedeler K. Axillary dissection of level I and II lymph nodes is important in breast cancer classification. The Danish Breast Cancer Cooperative Group (DBCG). Eur J Cancer 1992;28A(8–9):1415–8

    Article  PubMed  CAS  Google Scholar 

  63. Liberman L, Schneider L. Review of published evidence. In: Sentinel Lymph Node Biopsy. Edited by Hiram S Cody. Part III: Sentinel Lymph-Node Biopsy for Breast Cancer; chapter 27, 285–310. 2002, Martin Dunitz Ltd; London

    Google Scholar 

  64. Hansen NM, Grube BJ, Giuliano AE. The time has come to change the algorithm for the surgical management of early breast cancer. Arch Surg 2002;137(10):1131–5

    Article  PubMed  Google Scholar 

  65. Roumen RM, Kuijt GP, Liem IH, van Beek MW. Treatment of 100 patients with sentinel nodenegative breast cancer without further axillary dissection. Br J Surg 2001;88(12):1639–43

    Article  PubMed  CAS  Google Scholar 

  66. Chung MA, Steinhoff MM, Cady B. Clinical axillary recurrence in breast cancer patients after a negative sentinel node biopsy. Am J Surg 2002;184(4):310–4

    Article  PubMed  Google Scholar 

  67. Schrenk P, Hatzl-Griesenhofer M, Shamiyeh A, Waynad W. Follow-up of sentinel node negative breast cancer patients without axillary lymph node dissection. J Surg Oncol 2001;77(3):165–70

    Article  PubMed  CAS  Google Scholar 

  68. Cserni G, Amendoeira I, Apostolikas N, Bellocq JP, Bianchi S, et al. Pathological work-up of sentinel lymph nodes in breast cancer. Review of current data to be considered for the formulation of guidelines. Eur J Cancer 2003;39:1654–67

    Article  PubMed  CAS  Google Scholar 

  69. Giuliano AE, Jones RC, Brennan M, Statman R. Sentinel lymphadenectomy in breast cancer. J Clin Oncol 1997;15:2345–50

    PubMed  CAS  Google Scholar 

  70. Chu KU, Turner RR, Hansen NM, Brennan MB, Bilchik A, Giuliano AE. Do all patients with sentinel node metastasis from breast carcinoma need complete axillary node dissection? Ann Surg 1999;229:536–41

    Article  PubMed  CAS  Google Scholar 

  71. Reynolds C, Mick R, Donohue JH, Grant CS, Farley DR, et al. Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol 1999;17:1720–6

    PubMed  CAS  Google Scholar 

  72. Pendas S, Dauway E, Giuliano R, Ku N, Cox CE, Reintgen DS. Sentinel node biopsy in ductal carcinoma in situ patients. Ann Surg Oncol 2000;7:15–20

    Article  PubMed  CAS  Google Scholar 

  73. Moore KH, Thaler HT, Tan LK, Borgen PI, Cody HS 3rd. Immunohistochemically detected tumor cells in the sentinel lymph nodes of patients with breast carcinoma. Cancer 2004;100(5):929–34

    Article  PubMed  Google Scholar 

  74. Viale G, Maiorano E, Mazzarol G, Zurrida S, Galimberti V, et al. Histologic detection and clinical implications of micrometastases in axillary sentinel lymph nodes for patients with breast carcinoma. Cancer 2001;92: 1378–84

    Article  PubMed  CAS  Google Scholar 

  75. Dowlatshahi K, Fan M, Bloom KJ, Spitz DJ, Patel S, Snider HC Jr. Occult metastases in the sentinel lymph nodes of patients with early stage breast carcinoma: A preliminary study. Cancer 1999;86:990–6

    Article  PubMed  CAS  Google Scholar 

  76. Torrenga H, Rahusen FD, Meijer S, Borgstein PJ, van Diest PJ Sentinel node investigation in breast cancer: detailed analysis of the yield from step sectioning and immunohistochemistry. J Clin Pathol 2001;54:550–2

    Article  PubMed  CAS  Google Scholar 

  77. Meyer JS. Sentinel lymph node biopsy: strategies for pathologic examination of the specimen. J Surg Oncol 1998;69:212–18

    Article  PubMed  CAS  Google Scholar 

  78. Huvos AG, Hutter RV, Berg JW. Significance of axillary macrometastases and micrometastases in mammary cancer. Ann Surg 1971;173:44–6

    Article  PubMed  CAS  Google Scholar 

  79. Tjan-Heijnen VC, Bult P, Widt-Evert LM, Ruers TJ, Beex LV. Micro metastases in axillary lymph nodes: an increasing classification and treatment dilemma in breast cancer due to the introduction of the sentinel lymph node procedure. Breast Cancer Res Treat 2001;70:81–8

    Article  PubMed  CAS  Google Scholar 

  80. Krag D. Why perform randomized clinical trials for sentinel node surgery for breast cancer? Am J Surg 2001;182;411–3

    Article  PubMed  CAS  Google Scholar 

  81. Grube BJ, Giuliano AE. Observation of the breast cancer patient with a tumor-positive sentinel node: implications of the ACOSOG Z0011 trial. Semin Surg Oncol 2001;20:230–7

    Article  PubMed  CAS  Google Scholar 

  82. Bourez RL, Rutgers EJ. The European Organization for Research and Treatment of Cancer (EORTC) Breast Cancer Group: quality control of surgical trials. Surg Oncol Clin N Am 2001;10:807–19, ix

    PubMed  CAS  Google Scholar 

  83. Degnim AC, et al. Clinicopathologic features of metastasis in nonsentinel lymph nodes of breast carcinoma patients. Cancer 2003;98:2307–15

    Article  PubMed  Google Scholar 

  84. Schwartz GF, Giuliano AE, Veronesi U. Proceedings of the consensus conference on the role of sentinel lymph node biopsy in carcinoma of the breast, April 19–22, 2001, Philadelphia, Pennsylvania. Cancer 2002;94:2542–51

    Article  PubMed  Google Scholar 

  85. Schroder CP, Ruiters MH, de Jong S, Tiebosch AT, Wesseling J, Veenstra R, de Vries J, Hoekstra HJ, de Leij LF, de Vries EG. Detection of micrometastatic breast cancer by means of real time quantitative RT-PCR and immunostaining in perioperative blood samples and sentinel nodes. Int J Cancer 2003;106:611–8

    Article  PubMed  CAS  Google Scholar 

  86. Branagan G, Hughes D, Jeffrey M, Crane-Robinson C, Perry PM. Detection of micrometastases in lymph nodes from patients with breast cancer. Br J Surg 2002;89(1):86–9

    Article  PubMed  CAS  Google Scholar 

  87. Sakaguchi M, Virmani A, Dudak MW, et al. Clinical relevance of reverse transcriptase-polymerase chain reaction for the detection of axillary lymph node metastases in breast cancer. Ann Surg Oncol 2003;10(2):117–25

    Article  PubMed  Google Scholar 

  88. Manzotti M, Dell’Orto P, Maisonneuve P, Zurrida S, Mazzarol G, Viale G. Reverse transcription-polymerase chain reaction assay for multiple mRNA markers in the detection of breast cancer metastases in sentinel lymph nodes. Int J Cancer 2001;95(5):307–12

    Article  PubMed  CAS  Google Scholar 

  89. Cserni G. Overinterpretation of the role of cytokeratin 19 RT-PCR of sentinel nodes in breast carcinoma. Surgery 2003;133(1):124

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Surgery, The Netherlands Cancer Institute Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, 1066 CX, The Netherlands

    Emiel J. T. Rutgers

Authors
  1. Emiel J. T. Rutgers
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Dept. of Medical Oncology, Jules Bordet Institute, Boulevard de Waterloo, 215, 1000, Brussels, Belgium

    Martine J. Piccart MD, PhD  & Fatima Cardoso MD  & 

  2. Anderson Cancer Center, The University of Texas MD, 1515 Holcombe Blvd, Houston, TX, 77030-4095, USA

    Mien-Chie Hung PhD

  3. Dept. of Radiation Oncology, Hospital of the University of Pennsylvania, 3400 Spruce Street, Philadelphia, Pennsylvania, 19104-4283, USA

    Lawrence J. Solin MD

  4. Dept. of Surgery, Emory University Hospital, 1364 Clifton Road NE B206, Atlanta, Georgia, 30322-1059, USA

    William C. Wood MD

Rights and permissions

Reprints and permissions

Copyright information

© 2006 Springer-Verlag Berlin Heidelberg

About this chapter

Cite this chapter

Rutgers, E.J.T. (2006). Tailored Surgery for Early Breast Cancer: Biological Aspects. In: Piccart, M.J., Hung, MC., Solin, L.J., Cardoso, F., Wood, W.C. (eds) Breast Cancer and Molecular Medicine. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-540-28266-2_9

Download citation

  • DOI: https://doi.org/10.1007/978-3-540-28266-2_9

  • Publisher Name: Springer, Berlin, Heidelberg

  • Print ISBN: 978-3-540-28265-5

  • Online ISBN: 978-3-540-28266-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation